Insilico's co-CEO hopes 'we might have a chance to stop biological aging' after promising results from its fibrosis drug trial

TL;DR

Healthcare executives predict average life expectancy could surpass 100 years within a generation.
Affordability and accessibility of advanced medical care are major challenges.
AI drugmakers are targeting aging at its source; Insilico Medicine reported early positive results showing a decrease in predicted biological age with its experimental fibrosis drug.
The concept of 'healthspan' – the duration of healthy living – is becoming a key target for the health sector.
Wearable health technology and AI could personalize healthcare, potentially providing a personal doctor for billions.

Continuer la lecture de l'article original